ANGPTL6 and type 2 diabetes mellitus: Previous studies revealed increased serum concentrations of this anti-obesity hepatokine in individuals with metabolic syndrome and type 2 diabetes and decreased circulating ANGPTL6 levels in hemodialyzed individuals compared to healthy subjects [44,46,47].